EN
简体
繁体
EN
简体
繁体
About Us
Company Overview
Milestones
Our Team
Investors
Partnership & Recognition
Contact Us
CANbridge in Rare Disease Community
Pipeline & Products
Pipeline
Rare Oncology
Rare Diseases
Gene Therapy
Other Onc.
Approved Products
Hunterase®
Nerlynx®
Caphosol®
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Corporate Governance
Stock Information
Presentations & Webcasts
Analyst Coverage
Financial Calendar
Email Alert and IR Contact
Media & News
Media Reports
Press Release
Corporate Culture & Career
Corporate Culture
Open Positions
Financial Reports
2022
2022 Annual Report
2022 ESG Report
Annual Results Announcement for The Year Ended December 31, 2022
2022 Interim Report
Interim Results Announcement for the Six Months Ended 30 June,2022
2021
2021 Annual Report
Annual Results Announcement for The Year Ended December 31, 2021
2021 ESG Report